Guillaume Moulis1, Agnès Sommet2, Maryse Lapeyre-Mestre2, Jean-Louis Montastruc2. 1. Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France guillaume.moulis@univ-tlse3.fr. 2. Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, INSERM U1027, Toulouse, Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse and UMR 1027, Université de Toulouse III, Toulouse, France.
Abstract
OBJECTIVE: Each TNF-α inhibitor (TNFi) can induce lupus or lupus-like syndrome. Nevertheless, the risk may differ between drugs because of different apoptosis induction properties. The aim of this study was to assess the putative association of each TNFi with lupus or lupus-like-syndrome. METHODS: All spontaneous reports of TNFi-related lupus recorded in the French pharmacovigilance database between January 2000 and December 2012 were described. We conducted disproportionality analyses (case/non-case method) to assess the link between TNFi and lupus, calculating reporting odds ratios (RORs). We used isoniazid as positive control and acetaminophen as negative control. We performed sensitivity analyses to test for event-related and drug-related competition biases. RESULTS: Among 309 671 spontaneous reports, 5213 involved TNFi. Among these, 39 were lupus or lupus-like syndromes: 25 involved infliximab, 9 adalimumab and 5 etanercept. The male:female sex ratio was 0.1 and the mean age was 44.9 years. Among the 39 cases, 28% fulfilled at least four ACR criteria for SLE. Median time to lupus onset was 11 months. Cutaneous and rheumatological involvement were the most frequent. Antinuclear autoantibodies were present in all patients, with anti-DNA specificity in 77.8%. Improvement was observed after TNFi withdrawal. There was a significant association between TNFi and lupus (ROR = 7.72, 95% CI 5.50, 10.83). The ROR was similar for infliximab (10.97, 95% CI 7.27, 16.56) and adalimumab (9.03, 95% CI 4.64, 17.58) and was 4.02 (95% CI 1.66, 9.75) for etanercept. Sensitivity analyses led to similar results. CONCLUSION: Although CIs overlap, there is a clear trend towards a decreased risk with etanercept compared with monoclonal TNFis.
OBJECTIVE: Each TNF-α inhibitor (TNFi) can induce lupus or lupus-like syndrome. Nevertheless, the risk may differ between drugs because of different apoptosis induction properties. The aim of this study was to assess the putative association of each TNFi with lupus or lupus-like-syndrome. METHODS: All spontaneous reports of TNFi-related lupus recorded in the French pharmacovigilance database between January 2000 and December 2012 were described. We conducted disproportionality analyses (case/non-case method) to assess the link between TNFi and lupus, calculating reporting odds ratios (RORs). We used isoniazid as positive control and acetaminophen as negative control. We performed sensitivity analyses to test for event-related and drug-related competition biases. RESULTS: Among 309 671 spontaneous reports, 5213 involved TNFi. Among these, 39 were lupus or lupus-like syndromes: 25 involved infliximab, 9 adalimumab and 5 etanercept. The male:female sex ratio was 0.1 and the mean age was 44.9 years. Among the 39 cases, 28% fulfilled at least four ACR criteria for SLE. Median time to lupus onset was 11 months. Cutaneous and rheumatological involvement were the most frequent. Antinuclear autoantibodies were present in all patients, with anti-DNA specificity in 77.8%. Improvement was observed after TNFi withdrawal. There was a significant association between TNFi and lupus (ROR = 7.72, 95% CI 5.50, 10.83). The ROR was similar for infliximab (10.97, 95% CI 7.27, 16.56) and adalimumab (9.03, 95% CI 4.64, 17.58) and was 4.02 (95% CI 1.66, 9.75) for etanercept. Sensitivity analyses led to similar results. CONCLUSION: Although CIs overlap, there is a clear trend towards a decreased risk with etanercept compared with monoclonal TNFis.
Authors: Igor Kremenevski; Oliver Sander; Michael Sticherling; Martin Raithel; FirstName MiddleName LastName Journal: Dtsch Arztebl Int Date: 2022-02-11 Impact factor: 8.251
Authors: João Luiz Pereira Vaz; Vander Fernandes; Felipe Nogueira; Adriano Arnóbio; Roger A Levy Journal: Clin Rheumatol Date: 2015-12-17 Impact factor: 2.980
Authors: Meghna Jani; William G Dixon; Lianne Kersley-Fleet; Ian N Bruce; Hector Chinoy; Anne Barton; Mark Lunt; Kath Watson; Deborah P Symmons; Kimme L Hyrich Journal: RMD Open Date: 2017-01-17